A Phase II Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Refractory De Novo Diffuse Large B-cell Lymphoma
Bruton’s tyrosine kinase (btk) is an enzyme that cancer cells use to survive and grow. It has been implicated in the growth of B-cell cancers. In this study, researchers are assessing the safety and effectiveness of an inhibitor of btk called PCI-32765 in patients with diffuse large B-cell lymphoma (DLBCL) that has returned or progressed despite prior therapy.
PCI-32765 is a capsule that is taken orally (by mouth).